Investigation Report on China Nateglinide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||334098|
|出版日期||內容資訊||英文 30 Pages
|Nateglinide的中國市場 Investigation Report on China Nateglinide Market, 2010-2019|
|出版日期: 2015年07月02日||內容資訊: 英文 30 Pages||
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
There are about 90 million diabetes patients in today's China and 95% of them suffer from type 2 diabetes mellitus. And the number of potential patients might reach up to 200 million.
Entering China after 2000, insulin secretagogues agent is mainly used for the treatment of type 2 diabetes. Currently, there are only 3 kinds available in the Chinese market, namely, nateglinide, repaglinide and mitiglinide. They share the same mechanism of action, that is to say, they lower blood glucose by stimulating the release of insulin from the beta cells. Compared with sulfonylurea, insulin secretagogues agent reports shorter duration of glucose-lowering action and lower rate of hypoglycemia.
Insulin secretagogues agent can be used alone in patients with type 2 diabetes where non-drug treatment fail to work. For patients with type 2 diabetes where metformin alone fail to work, it can be used together with metformin so as to lower blood glucose better.
Developed by the Japanese company Ajinomoto, anateglinide is the new oral non-sulfonylurea drug for the treatment of type 2 diabetes mellitus (T2DM). First appearing in the Japanese market in 1999, anateglinide was marketed by Novartis in the US in 2001 and later entered China in 2003. Compared with other oral antidiabetic drugs, anateglinide features novel mechanism, fast onset, short duration of action, certain efficacy, flexible dose and good safety. Currently, anateglinide in the Chinese market mainly comes from Beijing Novartis (Trade Name: Starlix), Deyuan Pharm, Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Bei Jia) and Nanjing Hailing Pharmaceutical Co., Ltd (Trade Name: Qifu). Meanwhile, over ten local enterprises got the approval to produce nateglinide for they all see a huge potential market for nateglinide. However, since nateglinide came into the market later than repaglinide, its market impact still lags behind repaglinide. Therefore, it is difficult for nateglinide to substitute repaglinide in a short time.
According to CRI's market survey, Beijing Novartis Pharma Ltd. took up a market share of about 95% for sales value in 2014 while other companies like Deyuan Pharm, Luoxin Pharmacy Group Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd together occupied about 5% of the nateglinide market in China. The sales value of nateglinide was CNY 67 million in 2014 and CAGR during the period of 2005-2014 reached about 40%.
The market size of nateglinide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: